Subscribe
The Immunotherapy Series, Part Three: Policy and the FDA

Out of Patients with Matthew Zachary

The Immunotherapy Series, Part Three: Policy and the FDA

April 16, 2020

The Immunotherapy Series, Part Three: Policy and the FDA

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?

Special guests:

Meghan Gutierrez

Chief Executive Officer

Lymphoma Research Foundation

Leo David Wang, M.D., Ph.D.

Assistant Professor, Department of Immuno-Oncology

Assistant Professor, Department of Pediatrics

City Of Hope

This series is brought to you ad-free by Adaptive Biotechnologies

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Proudly supported by:

cover
Y’all Means All Communities are powered by people—and the variety of lives, jobs, schedules, and skills keep cities buzzing. Providing care means healthcare has to show up for "y’all" no matter the gender identity, work schedule, or preferred language.